Depo-Provera Brain Tumor Lawsuit: 2026 Full Guide

Never Miss a Lawsuit Update

Mark Lawfold as a Preferred Source so you never miss a settlement deadline or new filing.

The Depo-Provera brain tumor lawsuit is one of the most significant pharmaceutical cases moving through the U.S. court system in 2026. Thousands of women claim this popular birth control shot caused them to develop meningioma brain tumors, and Pfizer failed to warn them.

This guide covers everything you need to know right now. You’ll learn who qualifies, what settlement payouts could look like, and how to file before key deadlines pass.

Here’s one number that puts this into perspective: a major 2024 study in the BMJ found that long-term Depo-Provera users had a 5.6 times higher risk of developing intracranial meningiomas. That finding shook the medical and legal worlds.

This is also helpful — James Henry Lawsuit 2026: Full Settlement and Claim Guide

Whether you were diagnosed with a meningioma or suspect something isn’t right, this article breaks down every detail you need for 2026.

What Is the Depo-Provera Brain Tumor Lawsuit?

The Depo-Provera brain tumor lawsuit is a mass tort action against Pfizer Inc. alleging the company knew or should have known that its contraceptive injection could cause meningioma brain tumors.

Women across the country have filed individual lawsuits claiming Pfizer failed to include adequate warnings on the drug’s label. The core argument is straightforward: Pfizer had scientific evidence linking medroxyprogesterone acetate (the active ingredient) to meningiomas and chose not to warn patients or doctors.

These cases have been consolidated into a multidistrict litigation (MDL No. 3127) in the U.S. District Court for the Northern District of Alabama. Judge Liles C. Burke oversees the proceedings.

The lawsuits don’t claim that Depo-Provera is defective in a manufacturing sense. Instead, they focus on a “failure to warn” theory. That means Pfizer allegedly had enough data to know the risk existed but kept it off the label.

This matters because women trusted their doctors, and doctors trusted the drug’s label. If the label didn’t mention brain tumors, nobody had the chance to make an informed choice.

Depo-Provera Lawsuit in 2026: Where Things Stand

The Depo-Provera lawsuit enters 2026 in a critical phase. The MDL is past initial discovery, and bellwether trial selections are expected.

By early 2026, thousands of cases are pending in the MDL. New plaintiffs continue to file as awareness grows. The litigation is gaining momentum, and several key milestones are anticipated this year.

What’s expected in 2026:

• Bellwether trial pool narrowing and case selection
• Completion of key expert depositions
• Pfizer’s Daubert challenges to plaintiff expert testimony
• Possible early settlement discussions if bellwether outcomes favor plaintiffs

The pace of this MDL has been faster than some comparable pharmaceutical cases. Judge Burke has moved the docket efficiently, setting firm deadlines for both sides.

For plaintiffs, 2026 is a “watch and wait” year in many respects. But it’s not a passive year. Attorneys are building their strongest cases, gathering medical records, and lining up expert witnesses.

If you haven’t filed yet, 2026 is still a viable window. But that window is getting smaller with each passing month.

Depo-Provera Meningioma Lawsuit Explained

A meningioma is a tumor that forms on the membranes surrounding the brain and spinal cord. Most meningiomas are benign, but “benign” doesn’t mean harmless.

Even noncancerous meningiomas can cause serious problems. They press on the brain. They cause seizures, vision loss, headaches, and personality changes. Many require surgery, and that surgery carries its own risks.

The Depo-Provera meningioma lawsuit argues that this specific type of brain tumor is linked to prolonged exposure to medroxyprogesterone acetate. The drug is a synthetic progestin, and meningiomas are known to carry progesterone receptors.

Think of it this way: meningioma tumors have a lock, and progestin is the key. When you flood the body with synthetic progestin through regular injections, you’re essentially feeding any existing or developing tumor.

Key facts about meningiomas in this lawsuit:

• Meningiomas account for roughly 40% of all primary brain tumors
• About 80% of meningiomas have progesterone receptors
• Tumor growth is often accelerated by sustained progestin exposure
• Many plaintiffs report tumors growing during or shortly after Depo-Provera use

The lawsuits cover both Depo-Provera (intramuscular injection) and Depo-SubQ Provera 104 (subcutaneous version). Both contain medroxyprogesterone acetate.

Key Takeaway: The Depo-Provera brain tumor lawsuit is a mass tort in MDL No. 3127 alleging Pfizer failed to warn women that the contraceptive shot could cause meningioma brain tumors, with 2026 being a pivotal year for case progress.

Depo-Provera Lawsuit Settlement Amounts

No settlements have been reached yet in the Depo-Provera litigation as of early 2026. That said, legal analysts and attorneys have published projected settlement ranges based on comparable pharmaceutical cases.

Settlement amounts in mass tort cases like this one depend heavily on the severity of injury. A woman who needed brain surgery will likely receive far more than someone whose tumor was monitored without intervention.

These are projections only. Actual numbers will depend on bellwether trial results and any global settlement Pfizer agrees to.

Several factors affect individual claim value:

• Duration of Depo-Provera use (longer use generally means stronger claim)
• Tumor size and location
• Whether surgery was required
• Ongoing medical costs and lost wages
• Age at diagnosis

Keep in mind, pharmaceutical companies rarely settle before bellwether trials produce a verdict. Pfizer will want to see how juries respond before offering money. That’s just how the game works in mass tort litigation.

Who Qualifies for the Depo-Provera Lawsuit?

You may qualify for the Depo-Provera lawsuit if you received Depo-Provera injections and were later diagnosed with a meningioma brain tumor.

That’s the basic threshold. But eligibility is more specific than that.

General eligibility requirements:

• You received at least one Depo-Provera or Depo-SubQ Provera 104 injection
• You were diagnosed with an intracranial meningioma (confirmed by MRI, CT scan, biopsy, or surgery)
• Your diagnosis came during or after your use of Depo-Provera
• You are within the statute of limitations in your state

Stronger cases typically involve women who received the injections for one year or longer. The BMJ study showed that the risk increased significantly with prolonged use.

You don’t need to have had surgery to qualify. Women whose meningiomas are being monitored through regular imaging can still file.

Family members may also be eligible in cases where a woman passed away due to complications from a meningioma. Wrongful death claims are part of this litigation.

If you’re unsure about your medical history, your doctor’s office or pharmacy should have records of every Depo-Provera injection you received. Those records are central to building a case.

Depo-Provera Brain Tumor Lawsuit Update

As of 2026, the Depo-Provera brain tumor lawsuit update shows rapid growth in filings and a court system moving toward trial preparation.

The MDL in the Northern District of Alabama has seen a steady influx of cases since its establishment. Judge Burke has maintained an active case management schedule, pushing both sides through discovery.

Recent developments include:

• Thousands of cases now consolidated in MDL No. 3127
• Expert reports from neuro-oncologists and epidemiologists have been submitted
• Pfizer has produced internal documents during discovery
• The Plaintiff Steering Committee has been organized and is coordinating case strategy
• Several state court cases are proceeding in parallel outside the MDL

One of the most watched elements in 2026 is the Daubert hearing process. Pfizer is expected to challenge the admissibility of plaintiff expert testimony. If the court allows those experts to testify, it strengthens plaintiffs’ positions significantly.

The FDA’s updated label for Depo-Provera, which was revised in 2024 to include meningioma as a potential risk, is also being cited in court filings. Plaintiffs argue that this label change proves the risk was real and that the prior label was inadequate.

Key Takeaway: The Depo-Provera litigation is past the early procedural stage, with expert discovery underway and bellwether trial planning expected to define the next phase in 2026.

How to File a Depo-Provera Lawsuit

Filing a Depo-Provera lawsuit starts with contacting an attorney experienced in pharmaceutical mass tort cases. You don’t pay anything upfront because these cases operate on a contingency fee basis.

Here’s the typical filing process, step by step:

Step 1: Free Case Evaluation
You contact a law firm and share your medical history. They review whether you meet the basic eligibility criteria.

Step 2: Gather Medical Records
Your attorney will request records showing your Depo-Provera injection history and your meningioma diagnosis. This includes pharmacy records, doctor visit notes, imaging reports, and surgical records if applicable.

Step 3: File the Complaint
Your lawyer files a complaint in federal court. It will likely be transferred to MDL No. 3127 in Alabama if filed in federal court.

Step 4: Your Case Enters Discovery
Your case becomes part of the larger MDL process. You may need to provide additional medical documentation or answer written questions (interrogatories).

Step 5: Wait for Resolution
Most cases will be resolved through settlement or trial after bellwether cases are decided.

You don’t need to appear in court during the MDL process. Most of the work happens between your attorney and the court.

The Link Between Depo-Provera and Meningioma

The scientific link between Depo-Provera and meningioma is supported by multiple peer-reviewed studies. The connection centers on the drug’s active ingredient, medroxyprogesterone acetate, which is a synthetic progestin.

Meningioma tumors frequently express progesterone receptors. When a patient receives regular injections of a high-dose progestin like Depo-Provera, the hormone binds to those receptors. This can stimulate tumor growth.

The most significant study was published in the BMJ (British Medical Journal) in March 2024. Researchers analyzed data from over 18,000 women with intracranial meningiomas. The findings were striking:

• Women who used medroxyprogesterone acetate for one year or more had a 5.6 times higher risk of meningioma
• Women who used it for three years or more saw an even higher risk
• The risk remained elevated even after stopping the drug

This wasn’t the only study. French health authorities had already flagged the connection years earlier. In 2020, a French study linked prolonged use of injectable medroxyprogesterone acetate to increased meningioma rates.

What makes this evidence powerful in court is the dose-response relationship. The longer you use Depo-Provera, the higher your risk. That type of pattern is exactly what courts look for when determining causation.

Pfizer’s own research departments had access to this data. Plaintiffs argue the company ignored or downplayed these findings for years.

Depo-Provera Side Effects and Brain Tumors

Depo-Provera’s known side effects include weight gain, bone density loss, irregular bleeding, and mood changes. But brain tumors were not listed as a risk on the drug’s label until 2024.

That’s the crux of this lawsuit. Women were warned about minor side effects but not about the one that could put a tumor in their skull.

Common Depo-Provera side effects (previously listed):

• Irregular menstrual bleeding or spotting
• Weight gain (average of 5 to 10 pounds in the first year)
• Headaches
• Bone mineral density loss
• Mood changes, including depression
• Decreased libido

Side effect NOT previously listed:

• Intracranial meningioma (brain tumor)

The gap between what women were told and what the science showed is enormous. For a drug that was marketed as a simple, convenient birth control option, the hidden risk of a brain tumor changes everything.

It’s worth comparing this to another drug scandal. Cyproterone acetate, a different progestin used in Europe, had its meningioma risk flagged much earlier. Regulators in France acted quickly to restrict it. The question plaintiffs are asking is: why didn’t Pfizer and the FDA do the same with Depo-Provera?

Key Takeaway: Multiple studies show a direct, dose-dependent link between Depo-Provera use and meningioma development, with the 2024 BMJ study finding a 5.6x increased risk for long-term users.

Before you go further, consider reading Education Lawsuit Last Week: 2026 Payout and Filing Guide

Pfizer and the Depo-Provera Lawsuit

Pfizer Inc. is the primary defendant in the Depo-Provera brain tumor litigation. The company acquired Pharmacia & Upjohn, the original manufacturer of Depo-Provera, in 2003.

By acquiring Pharmacia, Pfizer inherited both the product and its liabilities. That means Pfizer is responsible for any failure-to-warn claims stretching back decades.

Pfizer has generated billions of dollars in revenue from Depo-Provera. The drug has been on the U.S. market since 1992 as a contraceptive, though medroxyprogesterone acetate was used for other conditions even earlier.

Pfizer’s expected legal defenses:

• The meningioma risk was not scientifically established at the time
• The FDA approved the drug’s label, so Pfizer followed regulatory requirements
• Plaintiffs’ brain tumors may have been caused by other factors
• The studies showing a link are observational, not randomized controlled trials

Plaintiffs counter these defenses by pointing to Pfizer’s own internal research. Discovery documents may reveal what the company knew and when it knew it.

The FDA defense is particularly interesting. Pfizer will likely argue it couldn’t change the label without FDA approval. But courts have previously rejected this argument in other pharmaceutical cases, most notably in the Levaquin litigation.

Pfizer is fighting this case aggressively. They have deep pockets and experienced legal teams. But the evidence against them continues to mount.

Depo-Provera Lawsuit Eligibility Requirements

Eligibility for the Depo-Provera lawsuit comes down to three core requirements: you used the drug, you developed a meningioma, and you’re within the legal filing window.

Let’s break each one down in detail.

Requirement 1: Documented Depo-Provera Use
You need proof that you received Depo-Provera injections. Pharmacy records, insurance claims, or medical chart entries all count. Even partial records can work if they show a pattern of use.

Requirement 2: Meningioma Diagnosis
You must have a confirmed intracranial meningioma diagnosis. This is typically shown through MRI or CT imaging, a pathology report from a biopsy, or surgical records from tumor removal.

Requirement 3: Statute of Limitations Compliance
Each state has its own filing deadline. In most states, the clock starts when you were diagnosed or when you reasonably should have known the connection between Depo-Provera and your tumor.

There is no minimum number of injections required to file. However, cases involving longer use periods are generally considered stronger because of the dose-response data from clinical studies.

Women who used Depo-SubQ Provera 104 are also eligible. It contains the same active ingredient at a slightly lower dose.

Depo-Provera Lawsuit Deadline in 2026

The deadline to file a Depo-Provera lawsuit depends on your state’s statute of limitations for personal injury or product liability claims. There is no single national deadline.

Most states give you two to three years from the date of diagnosis or discovery to file. Some states are more generous. A few are stricter.

State Statute of Limitations Examples:

“Discovery” is the key word here. It doesn’t just mean when you were diagnosed. It means when you knew, or should have known, that Depo-Provera might have caused your meningioma.

For many women, that discovery date may be relatively recent. The BMJ study was published in March 2024. The FDA label update came later that year. If you only learned about the connection in 2024 or 2025, your filing window may extend into 2026 or 2027.

But don’t assume you have unlimited time. Courts interpret “discovery” differently depending on the jurisdiction. Waiting too long is risky.

The safest move in 2026 is to get a case evaluation now. An attorney can determine your exact deadline based on your state and your personal timeline.

Key Takeaway: There is no single nationwide deadline to file a Depo-Provera lawsuit, but most states require filing within two to three years of discovering the connection between the drug and your meningioma, making 2026 a critical year for many potential plaintiffs.

Depo-Provera Meningioma Settlement Payout

The Depo-Provera meningioma settlement payout will depend on individual case factors, and no payouts have been distributed yet as of early 2026.

Settlement payouts in mass tort pharmaceutical cases are almost never one-size-fits-all. Each plaintiff’s compensation reflects the severity of their injury and the strength of their evidence.

Factors that determine your payout:

• Did you have surgery? Craniotomy cases are valued highest.
• Was the tumor malignant? While most meningiomas are benign, some are atypical or anaplastic. These carry higher values.
• Did the tumor recur? Recurrence after initial treatment increases damages.
• How long did you use Depo-Provera? Longer use strengthens the causation argument.
• What are your ongoing medical costs? Future treatment needs factor into compensation.
• Did you lose income? Lost wages and reduced earning capacity are compensable.
• Did you experience permanent disability? Vision loss, cognitive changes, or physical limitations increase claim value.

Looking at comparable pharmaceutical settlements for context:

These are rough comparisons. Every mass tort is different. The Depo-Provera cases may settle for more or less depending on how bellwether trials go.

Payouts won’t arrive quickly. Even after a settlement is reached, distribution takes time. Expect 12 to 24 months from settlement agreement to checks arriving.

Depo-Provera MDL Update for 2026

The Depo-Provera MDL (Multidistrict Litigation No. 3127) is headquartered in the Northern District of Alabama under Judge Liles C. Burke. In 2026, this MDL is moving into its most active phase.

An MDL is not a class action. It’s a tool federal courts use to consolidate similar cases for efficiency during the pretrial phase. Each plaintiff still has their own individual case.

2026 MDL milestones to watch:

• Fact discovery completion: Both sides are wrapping up document exchanges and depositions of key witnesses
• Expert discovery: Plaintiff and defense experts are submitting reports on causation, medical evidence, and damages
• Daubert hearings: The court will decide whether expert testimony is scientifically reliable enough to present at trial
• Bellwether case selection: A small group of cases will be chosen to go to trial first as test cases

The Plaintiff Steering Committee (PSC) is coordinating strategy across thousands of cases. This committee was appointed by Judge Burke to manage the litigation efficiently.

One important development: the number of cases in the MDL has grown substantially. Early 2025 estimates suggested several hundred cases. By 2026, that number has climbed into the thousands as more women come forward.

The speed of this MDL compared to others is notable. Some pharmaceutical MDLs drag on for five to seven years before bellwether trials. The Depo-Provera MDL appears to be on a faster track.

Depo-Provera Bellwether Trials: What to Expect

Bellwether trials are test cases selected from the larger MDL pool. They’re designed to show both sides how juries react to the evidence, and they often drive settlement negotiations.

In the Depo-Provera litigation, bellwether trials are expected to begin in late 2026 or early 2027. The exact timing depends on how quickly expert discovery and Daubert challenges are resolved.

How bellwether trials work:

• A handful of cases (usually 4 to 8) are selected from the full MDL pool
• Each case goes to trial individually before a jury
• The outcomes don’t bind other plaintiffs, but they set expectations
• If plaintiffs win big verdicts, Pfizer has more incentive to settle
• If Pfizer wins, it may embolden the company to fight harder

Think of bellwether trials like a preview for a movie. They show what the full-scale litigation would look like. If the preview is strong, the studio (in this case, Pfizer) might decide it’s cheaper to settle than to fight thousands of individual trials.

The cases selected for bellwether trials usually represent a range of injury severity. Some might involve women who had craniotomies. Others might involve smaller tumors that were monitored. This gives both sides a sense of how juries value different scenarios.

For plaintiffs waiting in the MDL, bellwether results are the single most important indicator of what your case might be worth.

Key Takeaway: Bellwether trials expected in late 2026 or early 2027 will be the most important catalyst for settlement discussions in the Depo-Provera brain tumor litigation.

Readers also liked: Cerebral Palsy Lawsuit: 2026 Settlements and Filing

Depo-Provera Brain Tumor Symptoms to Watch For

Meningioma brain tumor symptoms depend on the tumor’s size and location. Many small meningiomas cause no symptoms at all and are found by accident during unrelated imaging.

But as a meningioma grows, it presses on surrounding brain tissue. That pressure creates symptoms that can range from annoying to life-altering.

You may want to read Shocking Entertainment Lawsuit 2026: Claims and Payouts

Common meningioma symptoms:

• Persistent headaches that get worse over time
• Vision changes, including blurred or double vision
• Hearing loss or ringing in the ears
• Seizures (sometimes the first sign)
• Weakness or numbness in arms or legs
• Memory problems or confusion
• Personality or behavior changes
• Difficulty with balance or coordination
• Loss of smell

If you used Depo-Provera and experience any of these symptoms, request brain imaging from your doctor. An MRI with contrast is the gold standard for detecting meningiomas.

Important timing note: Symptoms may not appear for years after Depo-Provera use. Meningiomas are slow-growing tumors. A tumor that started forming while you were receiving injections might not cause symptoms until years after you stopped.

Some women discover their meningioma only after a car accident, a fall, or an unrelated medical scan reveals the tumor. By that point, it may have been growing silently for a long time.

If you’ve been diagnosed with a meningioma and you have a history of Depo-Provera use, the connection is worth investigating from both a medical and legal standpoint.

Is This a Depo-Provera Class Action Lawsuit?

The Depo-Provera litigation is not a class action lawsuit. It is a mass tort consolidated through a multidistrict litigation (MDL) process.

People often confuse these two things, but they work very differently. The distinction matters because it affects how much money you could receive and how much control you have over your case.

Class Action vs. Mass Tort:

In a class action, one settlement check gets divided among all members. That usually means smaller individual payments. In a mass tort like this one, your settlement reflects your personal damages.

That’s actually good news for Depo-Provera plaintiffs. A woman who underwent brain surgery and lost her job will be compensated differently than someone whose small tumor is being watched. The system recognizes that injuries aren’t equal.

The MDL process handles shared pretrial work efficiently. Things like document production, expert depositions, and legal motions happen once instead of thousands of times. But when it comes to settlement or trial, your case is your own.

Depo-Provera Lawsuit Evidence and Studies

The scientific evidence supporting the Depo-Provera brain tumor lawsuit comes from multiple international studies, FDA records, and internal company data uncovered through the discovery process.

Key studies cited in the litigation:

1. BMJ Study (March 2024)
This is the landmark study. Researchers examined a French national health database of over 18,000 meningioma cases. They found that prolonged use of injectable medroxyprogesterone acetate was associated with a 5.6-fold increased risk of intracranial meningioma.

2. French National Agency for Medicines and Health Products Safety (ANSM) Reports
France flagged the meningioma risk associated with progestins years before the BMJ study. Regulatory actions in France restricted certain progestins based on tumor risk data.

3. WHO International Agency for Research on Cancer
The WHO classified medroxyprogesterone acetate in relation to cancer risk. This classification provides additional context for the biological plausibility of the Depo-Provera meningioma link.

4. FDA Label Revision (2024)
The FDA updated the Depo-Provera label to include meningioma as a known risk. This label change is powerful evidence in court. It essentially confirms what plaintiffs have been arguing.

What makes this evidence strong in court:

• The dose-response relationship (more use equals higher risk) is a hallmark of causation
• The biological mechanism is well understood (progesterone receptor binding)
• The FDA’s own label change corroborates the risk
• Multiple independent studies from different countries reach similar conclusions

Pfizer will argue these studies are observational, not randomized controlled trials. But in pharmaceutical litigation, observational studies with strong dose-response patterns have been accepted as evidence of causation before.

The evidence file in this case is deep. And as discovery continues in 2026, more internal Pfizer documents may surface that strengthen the plaintiffs’ position.

Key Takeaway: The scientific evidence behind the Depo-Provera brain tumor lawsuit is extensive, anchored by a major 2024 BMJ study, supported by international regulatory actions, and bolstered by the FDA’s own decision to update the drug’s label to include meningioma as a risk.

Frequently Asked Questions

How much money can I get from a Depo-Provera brain tumor lawsuit?

Projected settlement amounts range from $50,000 to $750,000 or more, depending on injury severity.

Cases involving brain surgery and permanent disability are valued highest.

No settlements have been paid yet; payouts will begin after bellwether trials or a global settlement agreement.

What is the deadline to file a Depo-Provera lawsuit in 2026?

The deadline depends on your state’s statute of limitations, which is typically two to three years from the date of discovery.

Many women’s discovery dates may be linked to the 2024 BMJ study or FDA label change.

Contact an attorney now to confirm your specific deadline before it passes.

Does Depo-Provera really cause brain tumors?

A 2024 BMJ study found that long-term Depo-Provera users had a 5.6 times higher risk of developing intracranial meningiomas.

The FDA updated the drug’s label in 2024 to add meningioma as a potential risk.

The biological mechanism involves the drug’s synthetic progestin binding to progesterone receptors on meningioma tumors.

How do I know if I qualify for the Depo-Provera lawsuit?

You may qualify if you received Depo-Provera injections and were diagnosed with an intracranial meningioma.

You’ll need medical records showing both your injection history and your diagnosis.

An attorney can evaluate your case for free during an initial consultation.

How long will the Depo-Provera lawsuit take to settle?

Bellwether trials are expected in late 2026 or early 2027, with settlement discussions likely following.

Full resolution for most plaintiffs could take two to four years from where things stand now.

Mass tort pharmaceutical cases of this size typically take three to five years total from MDL creation to final payouts.

This litigation is real, the evidence is strong, and 2026 is a year where real progress will happen. If you used Depo-Provera and were diagnosed with a meningioma, your window to act is open right now.

Get your medical records together. Reach out for a free case evaluation. The timeline is moving, and being early is always better than being late.

Don't miss this — J&J Talc Lawsuit Update 2026: Facts, Claims and Payouts

Don't miss this — Philips CPAP Personal Injury Lawsuit Update 2026

This may also interest you — Finance Lawsuit April 2026: Settlement and Payout Updates

Never Miss a Lawsuit Update

Mark Lawfold as a Preferred Source so you never miss a settlement deadline or new filing.